1.Awareness and behaviors for patients′privacy protection among undergraduate nurses
Modern Clinical Nursing 2016;15(4):44-46,47
Objective To study the awareness and behaviors for patients′ privacy protection among undergraduate nurses. Method By using questionnaire, the survey was conducted among 100 undergraduate nurses. Results The score on the awareness and behaviors for patients′privacy protection was (15.84 ± 1.25). There were significant differences in the awareness and behaviors among different internship time, gender and hospitals (all P<0.05). Conclusions Awareness and behaviors for patients′privacy protection among undergraduate nurses are at a medium level. It is a demand to enhance the education on patients′privacy protection , especially to male undergraduate nurses and at the beginning of internship so as to prevent the patient-nurse disputes.
2.Clinical analysis between the obese and non-obese patients with type 2 diabetes mellitus
Min CHEN ; Xiaozheng FANG ; Manyun ZHANG
Chinese Journal of Primary Medicine and Pharmacy 2008;15(11):1772-1773
Objective To comprehend the metabolic disorder of the obese patients with type 2 diabetes mellitus(T2DM).Methods According to body mass index( BMI),176 cases of T2DM were divided into 2 groups;obesity(95 cases) and non-obesity(81 cases),the waist circumference(W) ,hip circumference(H) ,fasting plasma glucose(FBG) ,2-hour postprandial plasma glucose(2hBG) ,fasting blood insulin(FINS),2 hours postprandial blood insuline(2hINS), renal function, triglycetide(TG), total cholesterol(TC), high density lipoprotein cholesterol(HDL-C),low density lipoprotein-cholesterol(LDL-C ), glycosylated hemoglobin(HbA1c) and blood pressure(BP) were tested.Results The BMI,the ratio of W/H (WHR), serum uric acid (BUA), FINS, 2bINS, FCP and 2hCP in the obese group were higher than those in non-obese group(P <0.01);systolic blood pressure and diastolic blood pressure in obese patients were higher than those in the non-obese group(P >0.05) ,while the prevalence of abdorminal obesity.Hypertension significantly increased in obese group than those in non-obese group.Conclusion Among the T2DM ,metabolic disorder in obese patients is even more serious.It is very improtant for obese patients with T2DM to be given combined treatment to improve the metabolic disorder,that includes controlling blood glucose, decreasing weight and lightening insulin resistance.
3.Relationship between glucose fluctuation state and diabetic chronic complications in type 2 diabete mellitus
Xiaozheng FANG ; Min CHEN ; Manyun ZHANG
Chinese Journal of Primary Medicine and Pharmacy 2009;16(4):599-600
Objective To explore the relation between glucose fluctuation state and diabetic chronic compli-cations in type 2 diabetes mellitus. Methods 169 cases with type 2 diabetes mellitus were divided into two groups: 78 cases with constant high glucose(group Ⅰ) and 91 cases with glucose fluctuation state( group Ⅱ ). The clinical data such as fasting plasma glucose(FBG) ,fasting blood insulin(FINS) ,fasting blood C peptide,2 hours postprandial plasma glucose (2hPG) ,2 hours postprandial blood insuline (2hINS) ,2 hours postprandial blood C peptide, glycosy-lated hemoglobin A1c (HbA1c), and blood pressure (BP), body mass index ( BMI ), urinary albumin excretion rote (UAER) ,triglyeeride(TG) ,total cholesterol(TC) ,high density lipoprotein cholesterol(HDL-C) ,low density lipopro-tein cholesterol(LDL-C) were measured. Results 2hPG in group Ⅱ was much higher than that in group Ⅰ (P<0.01) ,but 2 hours postprandial blood insuline and 2 hours postprandial blood C peptide in group Ⅱ were much lower than those in group Ⅰ (P<0.01). The incidence of diabetic chronic complications was higher in group Ⅱ compared with that in group Ⅰ (P<0.01). Conclusion These findings suggest that glucose fluctuation state with type 2 dia-betes mellitus had increased diabetic chronic complications.
4.Clinical characteristics and prognosis for 126 patients with severe drug eruption
Jie LI ; Manyun MAO ; Ni TANG ; Rui ZHAI ; Wu ZHU ; Mei YI ; Mingliang CHEN
Journal of Central South University(Medical Sciences) 2017;42(8):953-957
Objective:To explore the clinical characteristics of various types of severe drug eruption and common sensitized drugs,and to provide clinical references for reducing the incidence of severe drug eruption.Methods:The clinical data regarding 126 cases of severe drug eruption were analyzed retrospectively from June 2009 to May 2017 in Xiangya Hospital,Central South University.Results:In the 126 cases of severe drug eruption,the distribution of men and women ratio was 1∶1.38.The length of stay was (12.7±9.8) d.The most common type was Steven-Johnson syndrome;the most dangerous type was drug-induced bullosa epidermolysis,The most common sensitized drug category in these patients was antibiotics;the most common single sensitizing drug was carbamazepine,following by allopurinol.Conclusion:Severe drug eruption occurs mostly in young and middle-aged people.Steven-Johnson syndrome is the most common type;drug hypersensitive syndrome has the longest length of hospital course.Mortality rate of drug-induced bullosa epidermolysis is the highest.Timely stop using of allergens,early using glucocorticoids,and timely combination of non-glucocorticoids treatment (such as intravenous immunogloblin,plasma exchange and hemodialysis),can improve the efficacy and reduce the complications and mortality.
5.Biotransformation differences of ginsenoside compound K mediated by the gut microbiota from diabetic patients and healthy subjects.
Sutianzi HUANG ; Li SHAO ; Manyun CHEN ; Lin WANG ; Jing LIU ; Wei ZHANG ; Weihua HUANG
Chinese Journal of Natural Medicines (English Ed.) 2023;21(10):723-729
Many natural products can be bio-converted by the gut microbiota to influence pertinent efficiency. Ginsenoside compound K (GCK) is a potential anti-type 2 diabetes (T2D) saponin, which is mainly bio-transformed into protopanaxadiol (PPD) by the gut microbiota. Studies have shown that the gut microbiota between diabetic patients and healthy subjects are significantly different. Herein, we aimed to characterize the biotransformation of GCK mediated by the gut microbiota from diabetic patients and healthy subjects. Based on 16S rRNA gene sequencing, the results indicated the bacterial profiles were considerably different between the two groups, especially Alistipes and Parabacteroides that increased in healthy subjects. The quantitative analysis of GCK and PPD showed that gut microbiota from the diabetic patients metabolized GCK slower than healthy subjects through liquid chromatography tandem mass spectrometry (LC-MS/MS). The selected strain A. finegoldii and P. merdae exhibited a different metabolic capability of GCK. In conclusion, the different biotransformation capacity for GCK may impact its anti-diabetic potency.
Humans
;
Gastrointestinal Microbiome/genetics*
;
Chromatography, Liquid/methods*
;
Healthy Volunteers
;
RNA, Ribosomal, 16S
;
Feces/microbiology*
;
Tandem Mass Spectrometry
;
Biotransformation
;
Diabetes Mellitus, Type 2/drug therapy*